Work

Editorial: Evolving non-invasive biomarkers: chemokines and multi-omic profiling in NSCLC immunotherapy response

Year: 2026

Type: editorial

Abstract: Immune checkpoint inhibitors (ICIs) have changed the treatment of non-small cell lung cancer (NSCLC), producing 24 durable disease control in a proportion of patients. However, treatment selection still depends largely on 25 biomarkers that capture only part of the tumor-immune interaction. Programmed death-ligand 1 (PD-L1) 26 expression and tumor mutational burden (TMB) remain clinically useful, but spatial and temporal heterogeneity, 27 assay variability, and reliance on a single tissue specimen limit their predictive accuracy (

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2026.2002791

Authors: Jacobo Rogado, Elisabet González del Portillo, Diego Casado Elía, Jaime Rubio-Perez

Institutions: Hospital Universitario de La Princesa, Hospital Universitario Rey Juan Carlos, Hospital Universitario General de Villalba, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801

OpenAlex ID: W7219896785

Cites: 4

Cited by:

Related to: 10